Eli Lilly has announced that a late-stage trial of its investigative candidate, donanemab, significantly slowed the cognitive and functional decline in people with early symptomatic Alzheimer's disease.
Lilly's investigative Alzheimer’s treatment slowed disease progression in late-stage trial
May 4, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Sanofi treatment for ultra-rare ASMD to be made available through LSDP
October 22, 2025 - - Latest News -
Sigma reports strong growth and upgraded synergies in first full year post-merger
October 22, 2025 - - Latest News -
IDT Australia sharpens strategy with cost savings and radiopharmaceutical focus
October 21, 2025 - - Latest News -
FOI reforms set back transparency decades and will impact public health decision-making
October 21, 2025 - - Latest News -
Astellas' XTANDI achieves landmark survival milestone in prostate cancer
October 21, 2025 - - Latest News -
Services Australia reports record number of processed PBS prescriptions
October 21, 2025 - - Latest News -
Endometriosis diagnoses in Australian GP clinics nearly double over a decade
October 21, 2025 - - Latest News